Background: Several domestically-manufactured nonavalent HPV vaccine candidates are in phase III clinical trials and their future availability may address the current dilemma of insufficient supply and high price of the overseas-manufactured nonavalent HPV vaccine in China. We compare the population-level effectiveness and cost-effectiveness of switching to nonavalent HPV vaccination in China.
Methods: We used a previously validated transmission model to project the lifetime costs and effectiveness of five same-vaccine and two mixed-vaccine strategies. Nonavalent HPV vaccines were assumed to be available and meet the production requirements for national vaccination between 2030 and 2050. All women living or projected to be born in China during 2023-2100 were considered. We adopted a societal perspective and determined optimal strategies using cost-effectiveness efficiency frontiers.
Findings: Under our pricing assumptions, switching to nonavalent vaccination was always cost-saving compared with maintaining the current bivalent vaccination programme, irrespective of the screening scenarios and the year when nonavalent vaccine was assumed to become available (status quo screening: net cost saving $2589-5211 million; improved screening: net cost saving $1852-3789 million). In the same-vaccine strategies, the optimal strategy changed from "routine nonavalent HPV vaccination with catch-up to age 18" to "switching from bivalent to nonavalent HPV vaccination" if nonavalent vaccination is available after 2035. Compared with the optimal same-vaccine strategy, adopting mixed schedules with bivalent and nonavalent vaccines would further save $1336-4280 million net costs and gain 87,000-833,000 QALYs, depending on the screening scenario and the year when nonavalent vaccine becomes available.
Interpretation: Switching from bivalent to nonavalent HPV vaccination is likely to be cost-saving and have a significant impact on reducing the cervical cancer burden in China.
Funding: Bill & Melinda Gates Foundation (INV-031449 and INV-003174) and CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-004).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889945 | PMC |
| http://dx.doi.org/10.1016/j.lanwpc.2025.101499 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-effectiveness analysis of switching from a bivalent to a nonavalent HPV vaccination programme in China: a modelling study.
Lancet Reg Health West Pac
March 2025
School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Background: Several domestically-manufactured nonavalent HPV vaccine candidates are in phase III clinical trials and their future availability may address the current dilemma of insufficient supply and high price of the overseas-manufactured nonavalent HPV vaccine in China. We compare the population-level effectiveness and cost-effectiveness of switching to nonavalent HPV vaccination in China.
Methods: We used a previously validated transmission model to project the lifetime costs and effectiveness of five same-vaccine and two mixed-vaccine strategies.
Human Papillomavirus Infection in Partners of Women Attending Cervical Cancer Screening: A Pilot Study on Prevalence, Distribution, and Potential Use of Vaccines.
Vaccines (Basel)
February 2025
Department of Health Promotion, Mother and Child Care, Internal Medicine, Medical Specialties G. D'Alessandro, University of Palermo, 90127 Palermo, Italy.
: Human Papillomavirus (HPV) cross-infection among couple's partners is a widespread event and could lead to persistent infections. Unfortunately, the influence of male sexual partners of HPV-positive women on their cervical lesions and the potential role of HPV vaccines have been under-investigated. We evaluated the HPV prevalence in male partners of HPV-infected women, focusing on the possible correlation between partners' cervical lesions and the role of HPV vaccination.
View Article and Find Full Text PDFPrevalence of Human Papillomavirus Genotypes in Unvaccinated 16-20-Year-Old Males in Quebec, Canada.
J Infect Dis
February 2025
Département de médecine sociale et préventive, Faculté de médecine, Université Laval, Québec G1V 0A6 Canada.
Background: The province of Quebec (Canada) has had a school-based Human Papillomavirus (HPV) vaccination program with high coverage since 2008, with more than 90% of girls having received at least one quadrivalent vaccine (4vHPV) dose by age 15. In 2018, Quebec was the first jurisdiction to switch to a mixed schedule (nonavalent+bivalent), and as such wanted to evaluate it. However, when devising an evaluation strategy for new vaccine schedules, the presence of herd effect needs to be ascertained.
View Article and Find Full Text PDFHigh Prevalence of High-Risk HPV Among People with and Without HIV: Insights into Risk Factors for Tailored Screening Approaches.
Microorganisms
December 2024
Infectious Diseases Unit, Vita-Salute San Raffaele University, 20132 Milan, Italy.
Men who have sex with men (MSM) and people with HIV are at increased risk of anal HPV infection and cancer. This study aimed to assess the prevalence of anal HPV among MSM with HIV (MWH) and without HIV (MWoH), as well as among MSM under and over 35 years. Factors associated with infection from high-risk (HR) HPV were investigated.
View Article and Find Full Text PDFA Comprehensive Evaluation of the HPV Neutralizing Antibodies in Guangzhou, China: A Comparative Study on Various HPV Vaccines.
Vaccines (Basel)
November 2024
School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China.
Background: The evaluation of HPV vaccine effectiveness is essential for informing public health strategies, yet there remains a gap in understanding humoral immune responses generated by different HPV vaccine formulations in regional populations. This study addresses this gap by evaluating the immunogenicity of the newly developed HPV vaccine Cecolin (Wantai), alongside various imported vaccines, including bivalent, quadrivalent, and nonavalent options available in China.
Methods: From March 2023 to June 2024, a total of 352 participants were enrolled, including 87 females aged 9-14 years who received two doses of the bivalent HPV vaccine (Cecolin), 215 females aged 15-45 years who were fully vaccinated with various HPV vaccines, and 50 non-recipients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!